The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.
 
Elizabeth Iannotti Buchbinder
Employment - Alexion Pharmaceuticals (I); Biodesix (I); Sanofi (I)
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Lilly; Merck; Novartis
 
Justine Vanessa Cohen
Consulting or Advisory Role - Bristol-Myers Squibb; Genzyme
 
Rizwan Haq
Consulting or Advisory Role - Tango Therapeutics
Research Funding - Bristol-Myers Squibb; Novartis
Patents, Royalties, Other Intellectual Property - Patents issued: Mass General Hospital, co-inventor (2014) Patents pending: Dana-Farber Cancer Institute, co-inventor
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Amgen; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Compass Therapeutics; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Donald P. Lawrence
No Relationships to Disclose
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
Deb Knoerzer
Employment - BioMed Valley Discoveries
Stock and Other Ownership Interests - BioMed Valley Discoveries
 
Ryan J. Sullivan
Consulting or Advisory Role - ACI Clinical; Array BioPharma; Asana Biosciences; Merck; Novartis; Replimune; Syndax; WorldCare Clinical, LLC
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Viralytics (Inst)
Other Relationship - Boehringer Ingelheim